• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ERBB2 Gene Record

  • Summary
  • Interactions
  • Claims
  • ERBB2 2064 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    2064
    ERB-B2 RECEPTOR TYROSINE KINASE 2
    ERBB2
    CD340
    HER-2
    HER-2/neu
    HER2
    MLN 19
    NEU
    NGL
    TKR1
    164870
    3430
    ENSG00000141736
    OTTHUMG00000179300
    P04626
    RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2
    ERBB2_HUMAN
    HER2 (ERBB2/neu)
    EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER3 (ERBB3)
    EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER4 (ERBB4)
    MLN19
    Metastatic lymph node gene 19 protein
    Proto-oncogene Neu
    Proto-oncogene c-ErbB-2
    Tyrosine kinase-type cell surface receptor HER2
    p185erbB2
    CD_antigen=CD340
    20
    PA27844
    RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 PRECURSOR (EC 2.7.1.112) (P185ERBB2) (C-ERBB-2) (NEU PROTO-ONCOGENE) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2) (MLN 19). [SOURCE:UNIPROT/SWISSPROT;ACC:P04626]
    Erbb2 tyrosine kinase receptor
    T14597
    VSCN2

    Gene Info:

    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Interpro Type Domain
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Interpro Acc IPR001245
    Uniprot Evidence 1: Evidence at protein level
    Human Readable Name DRUGGABLE GENOME
    Uniprot Status Swiss-Prot
    Human Readable Name KINASE
    Initial Gene Query HER2/ErbB2
    Counted Citations from 1950-2000 6422
    Target Subclass EGFR
    Target Subclass Kinase
    Target Main Class Receptors
    Transmembrane Helix Count 1
    Target Class Receptors
    Target Subclass EC:2.7.10.1
    Gene Biotype PROTEIN_CODING
    (26 More Sources)

    Gene Categories: Category Details

    KINASE
    TYROSINE KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Zhang et al., 1998, Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties., Oncogene
    Soria et al., 2012, Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors., Ann. Oncol.
    Gavai et al., 2009, Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases., J. Med. Chem.
    Scott et al., 1991, The effects of flosequinan on regional blood flow in normal man., Br J Clin Pharmacol
    Lorenzen et al., 2015, Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie., Eur. J. Cancer
    Kavuri et al., 2015, HER2 activating mutations are targets for colorectal cancer treatment., Cancer Discov
    Greulich et al., 2012, Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2., Proc. Natl. Acad. Sci. U.S.A.
    Grellety et al., 2016, A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy., Ann. Oncol.
    Boulbes et al., 2015, HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer., Mol Oncol
    Sartore-Bianchi et al., 2016, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial., Lancet Oncol.
    Manole et al., 2016, JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies., Cancer Res.
    Witkiewicz et al., 2014, CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models., Genes Cancer
    Clavarezza et al., 2016, Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials., Clin. Cancer Res.
    Satoh et al., 2014, Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study., J. Clin. Oncol.
    Johnston et al., 2009, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer., J. Clin. Oncol.
    Wisinski et al., 2016, Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer., Clin. Cancer Res.
    Baselga et al., 2016, Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer., Clin. Cancer Res.
    Guarneri et al., 2015, Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer., Oncologist
    Li et al., 2014, Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1., PLoS ONE
    Rexer et al., 2013, Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2., Clin. Cancer Res.
    de Martino et al., 2014, Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib., Cancer Biol. Ther.
    Biswas et al., 2016, Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response., Cold Spring Harb Mol Case Stud
    Zuo et al., 2016, Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer., Clin. Cancer Res.
    Morrison Joly et al., 2016, Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers., Cancer Res.
    Hecht et al., 2016, Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial., J. Clin. Oncol.
    Kotschy et al., 2016, The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models., Nature
    Leto et al., 2015, Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas., Clin. Cancer Res.
    Bertotti et al., 2011, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer., Cancer Discov
    Wainberg et al., 2010, Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo., Clin. Cancer Res.
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Secrier et al., 2016, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance., Nat. Genet.
    Bose et al., 2013, Activating HER2 mutations in HER2 gene amplification negative breast cancer., Cancer Discov
    Kancha et al., 2011, Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib., PLoS ONE
    Trowe et al., 2008, EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation., Clin. Cancer Res.
    Pan et al., 2015, Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy., PLoS ONE
    Hanker et al., 2013, Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies., Proc. Natl. Acad. Sci. U.S.A.
    Kim et al., 2008, The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines., Cancer Lett.
    Cancer Cell Line Encyclopedia Consortium. et al., 2015, Pharmacogenomic agreement between two cancer cell line data sets., Nature
    Lyu A et al., 2014, Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates., Eur J Med Chem
    Sridhar J et al., 2014, Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer., Bioorg Med Chem Lett
    Ali et al., 2014, Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy., J. Clin. Oncol.
    Lee et al., 2006, Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas., Clin. Cancer Res.
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
    Geyer et al., 2006, Lapatinib plus capecitabine for HER2-positive advanced breast cancer., N. Engl. J. Med.
    Xia et al., 2005, Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells., Oncogene
    Baselga et al., 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial., Lancet
    Lee et al., 2016, Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer., J. Clin. Oncol.
    Guarneri et al., 2012, Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study., J. Clin. Oncol.
    Blackwell et al., 2010, Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer., J. Clin. Oncol.
    Xia et al., 2002, Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways., Oncogene
    Johnston et al., 2006, Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer., Drugs Today
    Zhou et al., 2004, Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance., Int. J. Radiat. Oncol. Biol. Phys.
    Tevaarwerk et al., 2009, Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer., Clin Ther
    Vazquez-Martin et al., 2011, Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth., J. Cell. Physiol.
    Wood et al., 2004, A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells., Cancer Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Grana et al., 2003, Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance., Cancer Res.
    Burris, 2004, Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib., Oncologist
    Xia et al., 2004, Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016., Oncogene
    Langer, 2004, Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC., Int. J. Radiat. Oncol. Biol. Phys.
    Medina et al., 2008, Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases., Clin Ther
    Bachelot T et al., 2013, Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study., Lancet Oncol
    Lin NU et al., 2009, Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer., Clin Cancer Res
    Leary et al., 2015, Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)., Clin. Cancer Res.
    Franklin et al., 2004, Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex., Cancer Cell
    Yarlagadda B et al., 2019, Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma., NPJ Precis Oncol
    Meric-Bernstam F et al., 2019, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study., Lancet Oncol
    Hainsworth JD et al., 2018, Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study., J Clin Oncol
    Baselga et al., 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer., N. Engl. J. Med.
    Swain et al., 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer., N. Engl. J. Med.
    Blumenthal et al., 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer., Clin. Cancer Res.
    Martin et al., 2016, Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study., Ann. Oncol.
    Kodack et al., 2017, The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation., Sci Transl Med
    Sharon E et al., 2010, Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine., Head Neck Oncol
    von Minckwitz et al., 2009, Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study., J. Clin. Oncol.
    Bartsch et al., 2007, Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer., J. Clin. Oncol.
    Saura et al., 2014, Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer., J. Clin. Oncol.
    Safran et al., 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu., Cancer Invest.
    Martin et al., 2013, A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer., Eur. J. Cancer
    Chan et al., 2016, Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol.
    Awada et al., 2016, Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial., JAMA Oncol
    Hanker et al., 2017, An Acquired HER2(T798I) Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer., Cancer Discov
    Lopez et al., 2015, Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo., Mol. Cancer Ther.
    Kosaka et al., 2017, Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors., Cancer Res.
    Ma et al., 2017, Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer., Clin. Cancer Res.
    Gandhi et al., 2014, Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors., J. Clin. Oncol.
    Burstein et al., 2010, Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer., J. Clin. Oncol.
    Chow et al., 2013, Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer., Br. J. Cancer
    Lin et al., 2012, A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab., Breast Cancer Res. Treat.
    Canonici A et al., 2013, Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer., Oncotarget
    Martin M et al., 2017, Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol
    Singh H et al., 2018, U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer., Clin Cancer Res
    Wong et al., 2011, Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families., Clin. Cancer Res.
    Yu et al., 2002, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228., J. Natl. Cancer Inst.
    Jeong et al., 2017, HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF., Clin Colorectal Cancer
    Yonesaka et al., 2011, Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab., Sci Transl Med
    Aung et al., 2016, Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer., Cold Spring Harb Mol Case Stud
    Ring et al., 2015, Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer., Clin. Cancer Res.
    Takashima et al., 2014, Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer., Anticancer Res.
    André et al., 2014, Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet Oncol.
    Ding et al., 2014, Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells., Anticancer Drugs
    Bachelot et al., 2014, Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study., BMC Cancer
    Berns et al., 2007, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer., Cancer Cell
    Wang et al., 2011, PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib., BMC Cancer
    Saura et al., 2014, Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy., Clin. Cancer Res.
    Hamad et al., 2017, Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer., J Natl Compr Canc Netw
    Xiao et al., 2016, A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response., Mol. Cancer Ther.
    Finn et al., 2009, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro., Breast Cancer Res.
    Borley et al., 2014, Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network., Br. J. Cancer
    Bang et al., 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial., Lancet
    Tanaka et al., 2011, The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations., Clin. Cancer Res.
    Chuang et al., 2017, ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies., J Thorac Oncol
    Yu et al., 2015, Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092., PLoS ONE
    Espelin et al., 2016, Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer., Cancer Res.
    Lin et al., 2007, The role of trastuzumab in early stage breast cancer: current data and treatment recommendations., Curr Treat Options Oncol
    Levêque et al., 2008, Clinical pharmacology of trastuzumab., Curr Clin Pharmacol
    Treish et al., 2000, Pharmacology and therapeutic use of trastuzumab in breast cancer., Am J Health Syst Pharm
    Minuti et al., 2012, Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer., Br. J. Cancer
    Bookman et al., 2003, Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group., J. Clin. Oncol.
    McAlpine et al., 2009, HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy., BMC Cancer
    Fleming et al., 2010, Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study., Gynecol. Oncol.
    Diver et al., 2015, The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer., Oncologist
    Doi et al., 2015, Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors., Cancer Chemother. Pharmacol.
    Chlebowski et al., 1976, Metallophosphoryl and Apophosphoryl Alkaline Phosphatases., J. Biol. Chem.
    Bland et al., 1976, Rapid infusion of sodium bicarbonate and albumin into high-risk premature infants soon after birth: a controlled, prospective trial., Am. J. Obstet. Gynecol.
    Andre et al., 2010, Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab., J. Clin. Oncol.
    Jerusalem et al., 2011, Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer., Breast Cancer Res. Treat.
    1998, Pharmacogenomics at work., Nat Biotechnol
    Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One
    Beauclair S et al., 2007, Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity., Ann Oncol
    Stemmler et al., 2006, Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer., Oncol. Rep.
    Altundag et al., 2004, Adjuvant targeted therapy with trastuzumab may decrease metastatic capacity in specific group of oropharyngeal cancer patients: downregulation of E-cadherin-catenin complex by cooperative effect of erbB-2 and human papillomavirus type 16 E6/E7 protooncogenes., Med. Hypotheses
    Mazières et al., 2016, Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort., Ann. Oncol.
    Chakrabarty et al., 2013, Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors., Cancer Res.
    Piccart-Gebhart et al., 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer., N. Engl. J. Med.
    Santin et al., 2008, Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu., Int J Gynaecol Obstet
    Kinehara et al., 2015, Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer., Lung Cancer
    Marty et al., 2005, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group., J. Clin. Oncol.
    Slamon et al., 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2., N. Engl. J. Med.
    Hirotsu et al., 2017, Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient., Med. Oncol.
    Fader AN et al., 2018, Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu., J Clin Oncol
    Takahashi H et al., 2019, Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma., J Clin Oncol
    Li et al., 2015, HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib., Lung Cancer
    Perera et al., 2009, HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy., Proc. Natl. Acad. Sci. U.S.A.
    De Grève et al., 2012, Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu., Lung Cancer
    Cortés et al., 2015, Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial., Lancet Oncol.
    Goh et al., 2016, Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine., PLoS Med.
    Khelwatty et al., 2011, Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members., Int. J. Oncol.
    Tsai et al., 2015, Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells., Mol. Cancer Ther.
    Costa et al., 2016, Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas., J Thorac Oncol
    Kwak et al., 2013, Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation., Cancer
    Choudhury et al., 2016, Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations., J. Clin. Oncol.
    Suzawa et al., 2016, Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations., Cancer Sci.
    Janjigian et al., 2013, Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET., J. Nucl. Med.
    Peters S et al., 2018, Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program., J Thorac Oncol
    Suzuki et al., 2009, Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models., Cancer Sci.
    Suzuki et al., 2007, Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor., Cancer Sci.
    Shimizu et al., 2014, Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors., Clin. Cancer Res.
    Mu et al., 2014, AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models., J. Exp. Clin. Cancer Res.
    Wang et al., 2006, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors., Cancer Cell
    Karlan et al., 1994, Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells., Gynecol. Oncol.
    Konecny et al., 2001, HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer., Breast Cancer Res. Treat.
    Phillips et al., 2016, ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope., Mol. Cancer Ther.
    Nam et al., 2011, Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer., Cancer Lett.
    Láng et al., 2006, [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer]., Magy Onkol
    Spicer et al., 2015, Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours., Eur. J. Cancer
    Tanaka et al., 2014, Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2., Cancer Sci.
    Herrera-Abreu et al., 2016, Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer., Cancer Res.
    Gonzales et al., 2008, Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor., Mol. Cancer Ther.
    Kalous et al., 2012, Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib., Mol. Cancer Ther.
    Kris et al., 2015, Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors., Ann. Oncol.
    Nam et al., 2012, Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer., Mol. Cancer Ther.
    Strasser et al., 2006, 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2., Differentiation
    Lopez et al., 2014, Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo., Gynecol. Oncol.
    Ferrario et al., 2016, Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer., PLoS ONE
    Hurley et al., 2006, Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer., J. Clin. Oncol.
    Wada K et al., 2015, Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects., Bioorg Med Chem
    Takahashi Y et al., 2008, Nakijiquinones G-I, new sesquiterpenoid quinones from marine sponge., Bioorg Med Chem
    Nordstrom JL et al., 2011, Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties., Breast Cancer Res
    Bang et al., 2017, First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors., Ann. Oncol.
    Mackey et al., 2015, Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer., J. Clin. Oncol.
    Moulder et al., 2017, Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2(+)-Advanced Solid Tumors, with an Expansion Cohort in HER2(+) Metastatic Breast Cancer (MBC)., Clin. Cancer Res.
    Kulukian A et al., 2020, Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models., Mol Cancer Ther
    Borges VF et al., 2018, Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial., JAMA Oncol
    Prickett et al., 2009, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4., Nat. Genet.
    Basu et al., 2015, First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014., Clin. Cancer Res.
    Ring et al., 1996, Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter., Gene Ther.
    Jordan et al., 2016, HER2 expression identifies dynamic functional states within circulating breast cancer cells., Nature
    Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
    Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.
    Shah et al., 2017, Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial., JAMA Oncol
    Liu et al., 2007, Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells., Int. J. Cancer
    Raspollini et al., 2005, HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy., Pathol. Res. Pract.
    Kurokawa et al., 2001, Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer., Clin. Cancer Res.
    Takagi et al., 2014, HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285., Oncoscience
    Gravalos et al., 2008, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target., Ann. Oncol.
    Nakayama et al., 2013, Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model., J Cancer
    Wang et al., 2016, Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells., Mol. Cancer Ther.
    Chong et al., 2017, Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer., Gut
    Ma et al., 2017, Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer., J. Clin. Oncol.
    Krishnan et al., 2014, Targeting the disordered C terminus of PTP1B with an allosteric inhibitor., Nat. Chem. Biol.
    Ziemba et al., 2001, Repair of triplex-directed DNA alkylation by nucleotide excision repair., Nucleic Acids Res.
    Ortiz-Cuaran et al., 2016, Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors., Clin. Cancer Res.
    Utermark et al., 2012, The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis., Genes Dev.
    Yap et al., 2012, AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity., Clin. Cancer Res.
    Masui et al., 1991, Direct DNA sequencing of the rat neu oncogene transmembrane domain reveals no mutation in urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide or N-methyl-N-nitrosourea., Carcinogenesis
    Erjala et al., 2006, Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells., Clin. Cancer Res.
    Piechocki et al., 2007, Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu., Cancer Res.
    Carmi C et al., 2010, Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion., J Med Chem
    van der Lee et al., 2015, The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers., Mol. Cancer Ther.
    Black et al., 2016, SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression., Mol. Cancer Ther.
    Andrade-Vieira et al., 2014, Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss., Oncotarget
    Tang et al., 2015, BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers., Mol. Cancer Ther.
    Proia et al., 2015, 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity., Mol. Cancer Ther.
    Mocanu MM et al., 2014, Epigallocatechin 3-O-gallate induces 67 kDa laminin receptor-mediated cell death accompanied by downregulation of ErbB proteins and altered lipid raft clustering in mammary and epidermoid carcinoma cells., J Nat Prod
    Yeh et al., 1999, From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells., Proc. Natl. Acad. Sci. U.S.A.
    Venkatesan et al., 2010, PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor., Bioorg. Med. Chem. Lett.
    Ogitani et al., 2016, DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1., Clin. Cancer Res.
    Yan et al., 2013, Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068., Clin. Cancer Res.
    Esmat et al., 2006, Cytotoxicity of a natural anthraquinone (Aloin) against human breast cancer cell lines with and without ErbB-2: topoisomerase IIalpha coamplification., Cancer Biol. Ther.
    Miyagawa et al., 2004, Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol., Oncogene
    Hollestelle et al., 2007, Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines., Mol. Cancer Res.
    Mallon et al., 2011, Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor., Clin. Cancer Res.
    Sonnenblick et al., 2017, Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial., J. Clin. Oncol.
    Hart et al., 2013, VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer., Mol. Cancer Ther.
    Piechocki et al., 2006, Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu., Int. J. Cancer
  • TUCATINIB   ERBB2

    Interaction Score: 2.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type stomach carcinoma
    Approval Status Phase I
    Indication/Tumor Type Her2-receptor positive breast cancer

    PMIDs:
    28053022 32241871 29955792


    Sources:
    TALC TdgClinicalTrial JAX-CKB TTD

  • TRASTUZUMAB   ERBB2

    Interaction Score: 1.84

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Notes

    PMIDs:
    23220880 16397024 25157968 26243863 26619011 22908275 27626067 27108243 25370464 24982373 27140927 23801166 24742739 17679724 24300914 24606768 17936563 21676217 24470511 26245675 27697991 23948973 28784859 26880266 19874578 28539475 26296355 24691421 20728210 21558396 26432108 28167203 23940356 26469692 26759238 17660958 18690878 11752352 11098307 22850551 12525520 20003286 19840887 26099744 26104654 2605 2013 20975068 21107682 9788323 30071039 17693647 16596213 15236790 20504363 26598547 31453370 30857956 29320312 23204226 22257673 22149875 19289619 16236737 26874901 18555254 25693012 25601188 20124187 22493419 16091755 15911866 11248153 27900589 29146401 29523624 29584549 30452336


    Sources:
    TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB ChemblInteractions NCI DoCM CIViC PharmGKB TTD FDA OncoKB

  • NERATINIB   ERBB2

    Interaction Score: 1.41

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    combination therapy Capecitabine + Neratinib
    Approval Status FDA approved

    PMIDs:
    22908275 23953056 26874901 27078022 28274957 27697991 28539475 26333383 26243863 23220880 28363995 28679771 24323026 22046346 24516025 16397024 26619011 25157968 20142587 23632474 22418700 24009064 25287822 29146401 29523624


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions DoCM CIViC MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB

  • AFATINIB   ERBB2

    Interaction Score: 1.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Response Type conflicting
    Approval Status Phase I
    Indication/Tumor Type Her2-receptor positive breast cancer

    PMIDs:
    23632474 22418700 20142587 26559459 19122144 22325357 25370464 26596672 27923043 21617858 25589492 23948973 24971884 26243863 26964772 28274957 23775486 27044931 28363995 26545934 28167203 23578997 26296355 30096481


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB CIViC MyCancerGenomeClinicalTrial

  • TRASTUZUMAB DUOCARMAZINE   ERBB2

    Interaction Score: 1.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type uterine corpus serous adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25589493 27256376


    Sources:
    JAX-CKB

  • TAK-285   ERBB2

    Interaction Score: 1.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes
    Indication/Tumor Type Her2-receptor positive breast cancer

    PMIDs:
    25594012 18441328 23983820


    Sources:
    JAX-CKB ChemblInteractions TTD

  • MARGETUXIMAB   ERBB2

    Interaction Score: 1.26

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name MGAH22
    Novel drug target Established target
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

    PMIDs:
    22129105 28119295


    Sources:
    TdgClinicalTrial JAX-CKB ChemblInteractions TTD

  • LAPATINIB   ERBB2

    Interaction Score: 1.17

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy Lapatinib + Palbociclib
    combination therapy Entinostat + Lapatinib
    combination therapy Lapatinib + Paclitaxel

    PMIDs:
    2015169 25694417 26243863 22908275 26487584 25435280 27108243 27450453 25221644 27140927 24868024 19786658 27026198 26920887 26245675 25238247 23948973 24971884 27900369 27697991 27197158 26628478 27760111 26296355 22586653 20179222 26432108 27595477 23220880 22046346 18413839 26270481 23940356 18774637 26570998 25305330 24355130 24516025 16397024 26619011 25157968 17192538 16091755 22257673 26811533 22493419 20124187 12214266 16894399 14751502 20110044 20658522 15374980 11752352 14633707 15163842 14737100 14967461 18803986 23122784 19228746 25398453


    Sources:
    TALC DTC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB TEND DoCM CIViC PharmGKB TTD FDA OncoKB

  • PERTUZUMAB   ERBB2

    Interaction Score: 1.16

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes Prevents dimerization of HER2 with other HER receptors
    combination therapy Trastuzumab + Pertuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer

    PMIDs:
    15093539 31453370 30857956 29320312 22149875 25693012 23801166 27052654 28539475 22586653 23940356


    Sources:
    TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC PharmGKB TTD FDA OncoKB

  • DACOMITINIB   ERBB2

    Interaction Score: 1.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    18606718 22761403 25899785 22135232 28363995


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC MyCancerGenomeClinicalTrial TTD

  • S-222611   ERBB2

    Interaction Score: 1.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Indication/Tumor Type stomach cancer

    PMIDs:
    25434923 24837299


    Sources:
    JAX-CKB ChemblInteractions TTD

  • AC-480   ERBB2

    Interaction Score: 0.95

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name AC480
    Novel drug target Established target
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

    PMIDs:
    21576284 19821562


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TTD

  • TRASTUZUMAB DERUXTECAN   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical - Pdx & cell culture

    PMIDs:
    27026201


    Sources:
    JAX-CKB

  • T-DM1   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Docetaxel + T-DM1 + Pertuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    27052654


    Sources:
    JAX-CKB

  • NAKIJIQUINONE I   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18676149


    Sources:
    DTC

  • NAKIJIQUINONES G   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18676149


    Sources:
    DTC

  • GANCOTAMAB   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MM-302 + Trastuzumab
    Indication/Tumor Type stomach cancer
    Response Type sensitive

    PMIDs:
    26759238


    Sources:
    JAX-CKB ChemblInteractions TTD

  • MM-111   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    combination therapy Paclitaxel + Trastuzumab + MM-111
    Indication/Tumor Type stomach cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    MyCancerGenome TdgClinicalTrial JAX-CKB TTD

  • NAKIJIQUINONES H   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18676149


    Sources:
    DTC

  • CP-724714   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • VARLITINIB   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name ARRY-334543
    combination therapy trastuzumab + varlitinib

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial JAX-CKB ChemblInteractions TTD

  • SAPITINIB   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes

    PMIDs:
    24886365


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions TTD

  • MUBRITINIB   ERBB2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions

  • MP-412   ERBB2

    Interaction Score: 0.7

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    19459856 17888033


    Sources:
    TdgClinicalTrial JAX-CKB ChemblInteractions

  • PYROTINIB   ERBB2

    Interaction Score: 0.63

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    28498781


    Sources:
    JAX-CKB ChemblInteractions

  • IRESSA   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16470840


    Sources:
    NCI

  • ANTHRAQUINONE   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16357514


    Sources:
    NCI

  • TIPIRACIL   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Tipiracil,Trifluridine

    PMIDs:
    None found


    Sources:
    FDA

  • MASOPROCOL   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ZENOCUTUZUMAB   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ADO-TRASTUZUMAB EMTANSINE   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TRODUSQUEMINE   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    24845231


    Sources:
    JAX-CKB

  • MEDI-4276   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ONARTUZUMAB   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Onartuzumab + mFOLFOX6
    Indication/Tumor Type gastric adenocarcinoma
    Response Type no benefit

    PMIDs:
    27918764


    Sources:
    JAX-CKB

  • TESEVATINIB   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes
    Evidence Type Actionable

    PMIDs:
    19718025 18413839


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

  • ELGEMTUMAB   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy LJM716 + Neratinib
    Indication/Tumor Type breast cancer
    Response Type sensitive

    PMIDs:
    28539475


    Sources:
    JAX-CKB

  • HERCEPTIN   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17216002 15581051


    Sources:
    NCI

  • DEPATUXIZUMAB MAFODOTIN   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    26846818


    Sources:
    JAX-CKB

  • LAPULEUCEL-T   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type no benefit

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • INSM-18   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name INSM-18
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • HEMAY-022   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • POZIOTINIB   ERBB2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor inhibitor
    Direct Interaction yes
    Indication/Tumor Type stomach cancer

    PMIDs:
    21306821


    Sources:
    JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial

  • BMS-690514   ERBB2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Notes

    PMIDs:
    21531814


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions

  • PELITINIB   ERBB2

    Interaction Score: 0.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome

  • AEE-788   ERBB2

    Interaction Score: 0.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22046346


    Sources:
    MyCancerGenome JAX-CKB ChemblInteractions

  • ERTUMAXOMAB   ERBB2

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 other
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • CANERTINIB   ERBB2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    16843263


    Sources:
    MyCancerGenome JAX-CKB TTD

  • METHYLCURCUMIN   ERBB2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25753330


    Sources:
    DTC

  • PKI-179   ERBB2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    20797855


    Sources:
    JAX-CKB

  • DIMETHYLCURCUMIN   ERBB2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25753330


    Sources:
    DTC

  • URACIL   ERBB2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1682063


    Sources:
    NCI

  • MDX-210   ERBB2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 other
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • GANCICLOVIR   ERBB2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8986436


    Sources:
    NCI

  • LAPATINIB DITOSYLATE   ERBB2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ALLITINIB   ERBB2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CUDC-101   ERBB2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CUDC-101
    Novel drug target Established target
    Notes

    PMIDs:
    25107918


    Sources:
    TALC TdgClinicalTrial JAX-CKB ChemblInteractions TTD

  • RG-4733   ERBB2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy RO4929097 + Paclitaxel
    Indication/Tumor Type Her2-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    27556950


    Sources:
    JAX-CKB

  • LIFIRAFENIB   ERBB2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    26208524


    Sources:
    JAX-CKB

  • OSIMERTINIB   ERBB2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    27252416


    Sources:
    JAX-CKB

  • ERIBULIN   ERBB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • AFATINIB DIMALEATE   ERBB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TIVOZANIB   ERBB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy 23814 + Tivozanib
    Indication/Tumor Type breast cancer
    Response Type sensitive

    PMIDs:
    25995436


    Sources:
    JAX-CKB

  • RAMUCIRUMAB   ERBB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase III
    Response Type no benefit

    PMIDs:
    25185099


    Sources:
    JAX-CKB

  • CANERTINIB DIHYDROCHLORIDE   ERBB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TRIFLURIDINE   ERBB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Tipiracil,Trifluridine

    PMIDs:
    None found


    Sources:
    FDA

  • SERIBANTUMAB   ERBB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • IBRUTINIB   ERBB2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type esophageal cancer
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    27256378 28830912


    Sources:
    JAX-CKB CIViC

  • MK-2206   ERBB2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy KRIBB11 + MK2206
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type predicted – sensitive

    PMIDs:
    26104654 2605 2013 27026198


    Sources:
    JAX-CKB

  • IPATASERTIB   ERBB2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    24141624


    Sources:
    JAX-CKB

  • AT-13148   ERBB2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    22781553


    Sources:
    JAX-CKB

  • CAPECITABINE   ERBB2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    combination therapy Capecitabine + Neratinib
    combination therapy ARRY-380 + Capecitabine + Trastuzumab

    PMIDs:
    20504363 19289619 17192538 26487584 17679724 26920887 26432108 25287822


    Sources:
    JAX-CKB CIViC

  • TASELISIB   ERBB2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy GDC-0032 + Neratinib
    Indication/Tumor Type uterine corpus serous adenocarcinoma
    Response Type sensitive

    PMIDs:
    25172762 26333383


    Sources:
    JAX-CKB

  • VISTUSERTIB   ERBB2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type predicted – sensitive

    PMIDs:
    25805799


    Sources:
    JAX-CKB

  • OSIMERTINIB MESYLATE   ERBB2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • JNJ-26483327   ERBB2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • BUPARLISIB   ERBB2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BKM120 + Bevacizumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    24470511 23948973 28539475 23940356


    Sources:
    JAX-CKB

  • PILARALISIB   ERBB2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + XL147
    Evidence Type Actionable
    Approval Status Preclinical

    PMIDs:
    23948973 23204226


    Sources:
    JAX-CKB CIViC

  • FILGRASTIM   ERBB2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16549824


    Sources:
    NCI

  • CETUXIMAB   ERBB2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type resistant
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    28223103 22586653 23948973 21900593 26243863 26296355


    Sources:
    JAX-CKB CIViC

  • TALAZOPARIB   ERBB2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • VS-5584   ERBB2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type gastric adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    23270925


    Sources:
    JAX-CKB

  • CHLORAMBUCIL   ERBB2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11691913


    Sources:
    NCI

  • PA-799   ERBB2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian cancer
    combination therapy CH5132799 + Trastuzumab
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    21558396


    Sources:
    JAX-CKB

  • CRIZOTINIB   ERBB2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Crizotinib + Trastuzumab + Paclitaxel
    Indication/Tumor Type gastric adenocarcinoma
    Response Type sensitive

    PMIDs:
    27595477 26432108


    Sources:
    JAX-CKB

  • FULVESTRANT   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • PLUMBAGIN   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24355130


    Sources:
    DTC

  • EVEROLIMUS   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase III
    Response Type sensitive

    PMIDs:
    24742739 20975068 21107682


    Sources:
    JAX-CKB PharmGKB FDA

  • GEFITINIB   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    16818711 23220880 26545934 17638894 20151670


    Sources:
    DTC JAX-CKB NCI MyCancerGenomeClinicalTrial PharmGKB

  • LETROZOLE   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Lapatinib + Letrozole
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    19786658


    Sources:
    JAX-CKB

  • ABEMACICLIB   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • LEUCOVORIN   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    27626067 28784859 26432108


    Sources:
    JAX-CKB

  • FLOXURIDINE   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17177846


    Sources:
    NCI

  • AZD-8055   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25436981


    Sources:
    JAX-CKB

  • PICTILISIB   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Palbociclib + GDC-0941
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    27020857 22802530


    Sources:
    JAX-CKB CIViC

  • TEMSIROLIMUS   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type predicted – sensitive

    PMIDs:
    24323026


    Sources:
    JAX-CKB

  • PALBOCICLIB   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Palbociclib + Trastuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    25221644 27020857 19874578


    Sources:
    JAX-CKB PharmGKB FDA

  • DOCETAXEL   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Docetaxel + T-DM1 + Pertuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    22149875 25693012 30071039 25185099 23801166 27052654 30452336


    Sources:
    JAX-CKB CIViC PharmGKB

  • RIBOCICLIB   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • COPANLISIB   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    24170767


    Sources:
    JAX-CKB

  • VINORELBINE   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Phase Ib/II
    Response Type predicted – sensitive
    Indication/Tumor Type Her2-receptor negative breast cancer

    PMIDs:
    27992451 24742739


    Sources:
    JAX-CKB

  • OLAPARIB   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor negative breast cancer
    Response Type predicted – sensitive
    Approval Status Phase III

    PMIDs:
    None found


    Sources:
    JAX-CKB PharmGKB FDA

  • FIMEPINOSTAT   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22693356


    Sources:
    JAX-CKB

  • OXALIPLATIN   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    24300914 28784859 26432108


    Sources:
    JAX-CKB

  • ROMIDEPSIN   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11929951


    Sources:
    NCI

  • GEDATOLISIB   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    17314276 21325073


    Sources:
    JAX-CKB

  • BEVACIZUMAB   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BKM120 + Bevacizumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    26432108 23940356


    Sources:
    JAX-CKB

  • PANITUMUMAB   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    26243863


    Sources:
    JAX-CKB

  • IXABEPILONE   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • PACLITAXEL   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Pdx & cell culture
    Indication/Tumor Type inflammatory breast carcinoma
    combination therapy Sapitinib + Paclitaxel

    PMIDs:
    24886365 24868024 27078022 27556950 26432108 26469692 29584549


    Sources:
    JAX-CKB CIViC

  • PONATINIB   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Pdx
    Response Type no benefit

    PMIDs:
    26270481


    Sources:
    JAX-CKB

  • CI-1040   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    23948973


    Sources:
    JAX-CKB

  • ERLOTINIB   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type resistant
    Approval Status Clinical Study

    PMIDs:
    27900369


    Sources:
    DTC JAX-CKB PharmGKB

  • EPIGALOCATECHIN GALLATE   ERBB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24456004


    Sources:
    DTC

  • EMODIN   ERBB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9671406


    Sources:
    NCI

  • EXEMESTANE   ERBB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Exemestane + Seribantumab
    Indication/Tumor Type Her2-receptor negative breast cancer
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • DIETHYLSTILBESTROL   ERBB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14647453


    Sources:
    NCI

  • TAMOXIFEN   ERBB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17266042 15901136 11916237


    Sources:
    NCI

  • TRASTUZUMAB EMTANSINE   ERBB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • EPIRUBICIN   ERBB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11759828


    Sources:
    NCI

  • ALPELISIB   ERBB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • SELUMETINIB   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type decreased response

    PMIDs:
    24971884


    Sources:
    JAX-CKB

  • ENTINOSTAT   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Entinostat + Lapatinib + Trastuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • CHEMBL35482   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10318905


    Sources:
    NCI

  • HYDROCORTISONE   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7909787


    Sources:
    NCI

  • METFORMIN   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type predicted – sensitive
    Approval Status Phase III

    PMIDs:
    28375706


    Sources:
    JAX-CKB

  • SUNITINIB   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Sunitinib + Trastuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    24606768


    Sources:
    JAX-CKB

  • CARBOPLATIN   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039 29584549


    Sources:
    CIViC PharmGKB

  • FLUOROURACIL   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma

    PMIDs:
    27626067 28784859 26432108


    Sources:
    JAX-CKB

  • IRINOTECAN   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25601188


    Sources:
    CIViC

  • GEMCITABINE   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type predicted – sensitive

    PMIDs:
    15581051


    Sources:
    JAX-CKB NCI

  • SIROLIMUS   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19122144


    Sources:
    CIViC

  • CURCUMIN   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25753330


    Sources:
    DTC

  • GW843682X   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SORAFENIB   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Phase Ib/II
    Indication/Tumor Type Her2-receptor negative breast cancer
    combination therapy Sorafenib + Vinorelbine

    PMIDs:
    27992451


    Sources:
    JAX-CKB

  • ALISERTIB   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • GO-6976   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CEDIRANIB   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VANDETANIB   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SOTRASTAURIN   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DASATINIB   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYCLOPHOSPHAMIDE   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Guideline
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • R-406   ERBB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOXORUBICIN   ERBB2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Guideline
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • TAE-684   ERBB2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ILORASERTIB   ERBB2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CENISERTIB   ERBB2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   ERBB2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Gemcitabine + Sorafenib
    Indication/Tumor Type invasive bladder transitional cell carcinoma
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Ensembl: ENSG00000141736

    • Version: 101_38

    Alternate Names:
    ERBB2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • HopkinsGroom: P04626

    • Version: 11-September-2012

    Alternate Names:
    P04626 Uniprot Accession
    RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 Uniprot Protein Name
    2064 Entrez Gene Id

    Gene Info:
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Interpro Type Domain
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000141736

    • Version: 26-July-2011

    Alternate Names:
    RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 PRECURSOR (EC 2.7.1.112) (P185ERBB2) (C-ERBB-2) (NEU PROTO-ONCOGENE) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2) (MLN 19). [SOURCE:UNIPROT/SWISSPROT;ACC:P04626] Description
    ERBB2 Display Id
    ENSG00000141736 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • BaderLabGenes: ERBB2

    • Version: February-2014

    Alternate Names:
    2064 Entrez Gene ID

    Gene Info:
    Initial Gene Query HER2/ErbB2
    Counted Citations from 1950-2000 6422

    Gene Categories:
    KINASE

    Publications:

  • TdgClinicalTrial: P04626

    • Version: January-2014

    Alternate Names:
    ERBB2 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass EC:2.7.10.1

    Publications:

  • TEND: P04626

    • Version: 01-August-2011

    Alternate Names:
    P04626 Uniprot Accession
    ERBB2_HUMAN Uniprot Id
    2064 Entrez Gene Id

    Gene Info:
    Target Subclass EGFR
    Target Subclass Kinase
    Target Main Class Receptors

    Publications:

  • JAX-CKB: ERBB2

    • Version: 27-September-2017

    Alternate Names:
    2064 CKB Entrez Id
    ERBB2 CKB Gene Synonym
    CD340 CKB Gene Synonym

    Gene Info:

    Publications:
    Kancha et al., 2011, Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib., PLoS ONE
    Suzuki et al., 2007, Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor., Cancer Sci.
    Suzuki et al., 2009, Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models., Cancer Sci.

  • PharmGKB: ERBB2

    • Version: 18-August-2020

    Alternate Names:
    PA27844 PharmGKB ID

    Gene Info:

    Publications:
    Bose et al., 2013, Activating HER2 mutations in HER2 gene amplification negative breast cancer., Cancer Discov
    Cancer Cell Line Encyclopedia Consortium. et al., 2015, Pharmacogenomic agreement between two cancer cell line data sets., Nature
    Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One

  • CIViC: ERBB2

    • Version: 14-September-2020

    Alternate Names:
    2064 Entrez Gene ID
    20 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE, CLINICALLY ACTIONABLE

    Publications:
    Hirotsu et al., 2017, Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient., Med. Oncol.
    Krop et al., 2014, Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial., Lancet Oncol.
    Jhaveri KL et al., 2019, Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q., Ann Oncol

  • TTD: Erbb2 tyrosine kinase receptor

    • Version: 2020.06.01

    Alternate Names:
    HER2 TTD Gene Abbreviation
    T14597 TTD Target ID

    Gene Info:

    Publications:
    Dosio F et al., 2011, Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components., Toxins (Basel)
    Nordstrom JL et al., 2011, Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties., Breast Cancer Res

  • NCI: ERBB2

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Zhang et al., 1998, Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties., Oncogene
    Yu et al., 2002, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228., J. Natl. Cancer Inst.
    Strasser et al., 2006, 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2., Differentiation

  • DoCM: ERBB2

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    Greulich et al., 2012, Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2., Proc. Natl. Acad. Sci. U.S.A.
    MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn

  • DTC: ERBB2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Takahashi Y et al., 2008, Nakijiquinones G-I, new sesquiterpenoid quinones from marine sponge., Bioorg Med Chem
    Wada K et al., 2015, Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects., Bioorg Med Chem
    Gavai et al., 2009, Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases., J. Med. Chem.

  • MyCancerGenome: ERBB2

    • Version: 20-Jun-2017

    Alternate Names:
    2064 Entrez Gene Id
    ERBB2 MyCancerGenome Gene Symbol
    HER2 (ERBB2/neu) MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000141736

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000141736 Gene Symbol
    ERBB2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TALC: HER2

    • Version: 12-May-2016

    Alternate Names:
    HER2 Gene Symbol

    Gene Info:

    Publications:

  • ChemblInteractions: HER2

    • Version: chembl_23

    Alternate Names:
    MLN19 GENE_SYMBOL
    NEU GENE_SYMBOL
    NGL GENE_SYMBOL

    Gene Info:

    Publications:

  • OncoKB: ERBB2

    • Version: 23-July-2020

    Alternate Names:
    2064 OncoKB Entrez Id
    CD340 OncoKB Gene Synonym
    MLN 19 OncoKB Gene Synonym

    Gene Info:

    Publications:

  • GO: ERBB2

    • Version: 01-February-2022

    Alternate Names:
    HER2 GO Gene Synonym
    MLN19 GO Gene Synonym
    NEU GO Gene Synonym

    Gene Info:

    Gene Categories:
    TYROSINE KINASE

    Publications:

  • Tempus: ERBB2

    • Version: 11-November-2018

    Alternate Names:
    ERBB2 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: ERBB2

    • Version: 27-Jun-2013

    Alternate Names:
    2064 Gene ID
    CD340 dGene Synonym
    HER-2 dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, TYROSINE KINASE

    Publications:

  • Pharos: ERBB2

    • Version: 01-February-2022

    Alternate Names:
    Receptor tyrosine-protein kinase erbB-2 Gene Name
    P04626 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • MskImpact: ERBB2

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationClinicalTrial: ERBB2

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationBiomarkers: ERBB2

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • MyCancerGenomeClinicalTrial: ERBB2

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: ERBB2

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: ERBB2

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FDA: ERBB2

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

  • Oncomine: ERBB2

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21